ProPhase Labs, Inc.
PRPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000868278
No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding ProPhase Labs, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 23 | 21 | −2 |
| Shares | 1.60M | 1.65M | +42.4K (+2.6%) |
| Value | $9.95M | $8.56M | −$1.39M (−13.9%) |
New holders (4)
Institutions that held ProPhase Labs, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bank of Montreal | 158,587 | $821.0K | 0.00% |
| Marshall Wace, LLP | 22,801 | $119.0K | 0.00% |
| HighVista Strategies LLC | 20,256 | $105.0K | 0.07% |
| JPMorgan Chase & Co | 5,730 | $30.0K | 0.00% |
Sold out (6)
Institutions that held ProPhase Labs, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Millennium Management LLC | 46,575 | $289.0K |
| Acadian Asset Management LLC | 21,123 | $131.0K |
| Dimensional Fund Advisors LP | 19,530 | $121.0K |
| UBS Group AG | 9,040 | $56.0K |
| Tower Research Capital LLC (TRC) | 1,471 | $9.00K |
| Advisory Services Network, LLC | 600 | $4.00K |